Pricing Log in Create free account
Saturday 17 October 2026 Export STVN’s income statement to Excel — free account

Stevanato Group S.p.A.

STVN Healthcare Medical Instruments & Supplies

Stevanato Group S.p.A.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 12.3% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS fell 25.0%, free cash flow fell 167.0% and total debt rose 9.27%, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for five, operating cash flow growth for three.

18.90 0.35 −1.82%
Market cap
$5.3B
P/E
33.8×
Fwd P/E
27.5×
Dividend yield
0.33%
F-score
5/9
Altman Z
4.48
Beneish M
−2.79
Dividend safety
63/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.56
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — 4 — 3 1 —
Insider Ownership 82.08%

Capital & Financial Ratios $m

Market Cap 5,260.00
Revenue 1,425.27
Net Income 219.65
Free Cash Flow (34.67)
Net Debt 410.79
Current Ratio 1.61 (at or above 1.5: strong)
Debt/Equity 0.29 (at or below 0.5: strong)
P/E ratio 33.75
Fwd P/E 27.50
P/S ratio 3.62
P/B ratio 2.86
Past 5Y EPS Growth 9.21%
This Y EPS Growth 12.10%
Next Y EPS Growth 19.53% (at or above 15%: strong)
Next Y revenue growth (5.38%) (below 0%: weak)
Next 5Y EPS Growth 16.77% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.9×, against a ten-year median of 5.1×; over the ten years it ranged from 3.0× in 2026 to 8.0× in 2023.
P/E against its own 10 years 26.59%
10-year low 10-year high
P/S against its own 10 years 7.95%
10-year low 10-year high
P/B against its own 10 years 8.33%
10-year low 10-year high
EV/Sales against its own 10 years 11.52%
10-year low 10-year high

Dividends

Payout Ratio 0.11
Annual Dividend Rate 0.06
Annual Dividend Yield 0.33%
total individual payouts
2026 0.08
0.06
2025 0.06
0.06
2024 0.06
0.06
2023 0.06
0.06
2022 0.05
0.05
2021 Powerpack
2020 Powerpack
2019 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 80 108 160 108
Receivables 390 397 400 418
Inventory 276 265 303 359
Other 187 183 204 199
933 952 1,067 1,084
2023 2024 2025 Q'26
Payables 301 250 298 298
ST’ Debt 155 127 140 148
Other 133 113 143 172
622 517 606 672

Compound Annual Growth %

10y 5y 3y
Sales — 12.16% 9.00%
Cash Flow — 12.73% 43.80%
Earnings — 12.02% 1.68%
Book Value — 36.55% 17.03%

Revenue $m

Mar Jun Sep Dec Year
’26 320 351 — — —
’25 270 318 354 400 1,342
’24 256 280 306 353 1,195
’23 255 278 295 345 1,175
’22 238 249 247 302 1,036
’21 232 246 253 267 998
’20 150 178 184 — 756
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 88 36 — — —
’25 105 59 60 99 324
’24 78 23 22 45 169
’23 40 27 36 10 114
’22 6 45 (7) 65 109
’21 7 65 20 66 158
’20 (10) 59 62 178 178
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 6 (39) — — —
’25 31 (15) (1) (1) 15
’24 (34) (50) (34) (50) (167)
’23 (98) (77) (107) (81) (364)
’22 (56) (34) (42) (15) (147)
’21 (20) 37 (13) 22 25
’20 (10) 59 62 76 68
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.12 0.09 — — —
’25 0.11 0.12 0.15 0.20 0.58
’24 0.08 0.09 0.12 0.19 0.47
’23 0.12 0.14 0.15 0.18 0.60
’22 0.11 0.13 0.14 0.18 0.57
’21 0.18 0.17 0.08 0.20 0.63
’20 0.03 0.09 0.07 — 0.37
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.8
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 16.61 13.36 17.31 16.56 17.81

Analyst estimates 2026–2028

Powerpack
High — — — — — 29.18 23.30 36.30 34.73 28.00
People
People Employees — — — — 4,344 4,652 5,260 5,635 5,521 6,010
Revenue/emp, $m — — — 0.00 0.17 0.21 0.20 0.21 0.22 0.22
Income, $m
Income, $m Revenue — — — 601 756 998 1,036 1,175 1,195 1,342
Gross margin, % — — — 24.29 29.33 31.45 32.51 31.32 27.38 28.99
EBT — — — 62 110 196 198 205 173 214
EBT margin, % — — — 10.32 14.54 19.63 19.08 17.46 14.52 15.94
Net income — 0 — 44 110 196 198 205 173 214
Depreciation — — — 52 62 67 68 85 87 100
Per share, $
Per share, $ Revenue — — — 2.27 3.14 3.95 3.92 4.43 4.41 4.92
Earnings — — — 0.17 0.37 0.63 0.57 0.60 0.47 0.58
Cash flow — — — 0.18 0.74 0.62 0.41 0.43 0.62 1.19
Capex — — — 0.00 (0.46) (0.52) (0.97) (1.80) (1.24) (1.13)
Free cash flow — — — 0.18 0.28 0.10 (0.56) (1.37) (0.62) 0.05
Book value — — — 1.12 1.47 3.94 3.96 4.63 5.60 6.16
Shares, m — — — 265 241 253 265 265 271 273
Valuation, ×
Valuation, × P/E — — — 38.33 38.33 35.45 31.23 45.03 45.40 34.69
P/S — — — 5.64 5.64 5.68 4.47 5.99 4.95 4.09
P/B — — — 10.31 10.31 5.70 4.41 5.74 3.89 3.27
EV/Sales — — — 5.95 5.95 5.46 4.42 6.29 5.25 4.37
EV/FCF — — — 16.05 16.05 215.94 (31.15) (20.32) (37.47) 401.67
Cash, $m
Cash, $m Operating cash flow — — — 48 178 158 109 114 169 324
Capex — — — (83) (110) (133) (256) (478) (336) (309)
Free cash flow — — — 48 68 25 (147) (364) (167) 15
Balance, $m
Balance, $m Working capital — — — 210 202 624 404 311 436 461
Total debt — — — 433 429 294 231 432 470 533
Net debt — — — 291 249 (225) (45) 352 363 373
Shareholders’ equity — — — 298 354 996 1,049 1,226 1,520 1,682
Returns, %
Returns, % ROA — — — 8.89 8.56 11.41 8.78 7.90 5.35 5.86
ROIC — — — 0.00 12.20 15.55 12.62 8.61 5.79 6.84
ROE — — — 12.98 27.50 23.54 14.72 13.86 9.28 9.88
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Stevanato Group S.p.A. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ATR AptarGroup, Inc. $7.9B 22.2× 21.0× +6.26% (above 0%: growing) −18.34% (below 0%: shrinking) −23.07% (below 0%: shrinking) 35.61% 12.34% Compare
BLCO Bausch + Lomb Corporation $6.0B — (loss-making) — (loss-making) +9.08% (above 0%: growing) n/m +251.85% (above 0%: growing) 62.20% 5.95% Compare
TFX Teleflex Incorporated $5.4B — (loss-making) 45.3× +28.88% (above 0%: growing) −17.33% (below 0%: shrinking) +220.14% (above 0%: growing) 58.16% 12.77% Compare
MMSI Merit Medical Systems, Inc. $5.4B 36.4× 23.4× +9.51% (above 0%: growing) +18.18% (above 0%: growing) −25.66% (below 0%: shrinking) 51.37% 14.42% Compare
STVN Stevanato Group S.p.A. $5.3B 33.8× 27.5× +10.46% (above 0%: growing) −25.00% (below 0%: shrinking) −167.02% (below 0%: shrinking) 28.75% 12.93%
ICUI ICU Medical, Inc. $4.2B 136× 49.5× +0.51% (above 0%: growing) −46.85% (below 0%: shrinking) +655.98% (above 0%: growing) 42.61% 7.09% Compare
NVST Envista Holdings Corporation $3.8B 38.8× 24.4× +7.10% (above 0%: growing) +106.25% (above 0%: growing) +37.57% (above 0%: growing) 55.72% 10.99% Compare
PLSE Pulse Biosciences, Inc $3.3B — (loss-making) — (loss-making) +4,922.22% (above 0%: growing) n/m −45.39% (below 0%: shrinking) 37.10% (5,823.04%) Compare
WRBY Warby Parker Inc. $3.0B 334× 122× +9.81% (above 0%: growing) n/m −71.75% (below 0%: shrinking) 57.94% 1.34% Compare
Median of peers $4.8B 38.8× 34.8× +9.30% −17.33% +7.25% 53.55% 9.04%

All 55 Medical Instruments & Supplies stocks →

Stevanato Group S.p.A. (STVN) key facts

  • Strength: Stevanato Group S.p.A.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 12.3% from fiscal 2024.
  • Strength: Net income was $214.0 million, or $0.58 per share (basic), a net margin of 11.8%.
  • Stevanato Group S.p.A. (STVN) is a Medical Instruments & Supplies company in the Healthcare sector, listed on the New York Stock Exchange.
  • As of October 16, 2026, STVN traded at $18.90, a market capitalization of $5.3 billion.
  • At that price the stock trades at 33.8× trailing-twelve-month earnings and 3.6× sales; its P/E is higher than 27% of its own readings over the past ten years.
  • Stevanato Group S.p.A. pays an annual dividend of $0.06 per share, a yield of 0.33%, with a payout ratio of 11.2%.
  • Return on equity was 9.88% and debt-to-equity 0.29.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 4.48 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Stevanato Group S.p.A. (STVN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/STVN · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com